Central histaminergic modulation of H1 rather than H2-receptors has been shown to modify epileptic activity. Compounds acting on the HIC- and H3-receptors were tested against chemically-induced seizures in mice. Compounds antagonising the microsomal and nuclear intracellular receptors (HIC) only modified seizures at doses where toxicity was observed. Antagonists of the histamine H3-receptor (thioperamide and burimamide) only potentiated the severity of clonic convulsions induced by picrotoxin, while impromidine (i.c.v.), an antagonist with H2-agonist activity, inhibited leptazol-induced seizures. The H3-agonist, (R)alpha-methylhistamine, potentiated chemically-induced seizures, but at lower doses there was slight inhibition.
IntroductionHistamine H 1 -receptor antagonists are known to influence seizure susceptibility in humans [1] and mice [2]. However, the evidence for the role of the histamine H 2 -receptor in seizures is poor and conflicting [3]. Using the histamine H 2 -agonist dimaprit and histamine H 2 -antagonist zolantidine, histamine H 2 -receptor modulation was evaluated in 2 mouse seizure models. These models were chemically-induced, pentylenetetrazol (leptazol), which produced both clonic and tonic seizures and the audiogenic susceptible DBA/2 strain of mouse [4].
Materials and methods
Chemically induced-seizures in miceEither a subcutaneous (s.c.) injection of leptazol (55-60 mg/kg) which caused clonic seizures in 40-80% of the control group or a intravenous (i.v.) infusion (0.61 ml/min into the tail vein) of 0.5% w/v leptazol solution which caused both clonic and tonic seizures were used. The leptazol was administered 20 min after treatment to groups of BK/TO or CD1 mice (30-60 g) after treatment with saline (10 ml/kg) or drug (s.c.).
Audiogenic seizures in DBA/2 mice25 -29 days old DBA/2 mice(5-13 g) were exposed to auditory stimulation 20 min after s. c. injection of either vehicle or drug. For up to a maximum of 45 s a bell was rung (95 dB) 30 cm above the mice. The resulting behaviours were scored: 1 = wild running, 2 = clonus, 3 = tonus and 4 = respiratory arrest RA [6].
Results and discussionDimaprit (0.3-3 mg/kg) produced a bell shaped dose-related decrease in the s.c. leptazol-seizure model in male BK/TO mice (n = 30-60) (Fig. 1), with significant anticonvulsant effects at 0.3 and 3.0 mg/kg (p < 0.01) and at 1 mg/kg (p < 0.001) in the occurrence of seizure incidence. The severity (total of seizures observed within each of the groups) of the seizures was also reduced in a dose-related manner with both 0.3 and 3 mg/kg showing significant differences (p < 0.05) and 1 mg/kg (p < 0.01). However, zolantidine (3 and 10 mg/kg) was ineffective in this model in male BK/TO mice (n = 20-50).In the leptazol infusion model in female BK/TO mice, dimaprit (1 mg/kg) increased the leptazol dose needed to evoke tonic seizures by nearly 50% (65.73 ± 4.66 mg/kg in the controls compared to 92.46 ± 9.86 mg/kg (p < 0.05)). Fig. 1. Effect of dimaprit (s.c.) on the incidence of clonic seizures resulting from subcutaneous administration of leptazol (55 -60mg/kg) in male BK/TO mice (n = 30 -60). * p < 0.01, ** p < 0.001.Whereas, zolantidine (10 mg/kg) reduced the amount of leptazol needed to evoke clonic seizure in female CD1 mice (n = 15-17) by over 10% (43.94 ± 2.61 mg/kg in the controls, compared with 38.13 ± 1.40 mg/kg in the dosed group (p < 0.05)) (n = 15-17).In audiogenic susceptible mice, dimaprit (0.3-3mg/kg) produced a bell-shaped dose-dependent effect. The mean seizure score of 3.20 in the controls was reduced to 2.25 in the dimaprit group (1 mg/kg). Dimaprit (0.3-1 mg/kg) significantly reduced wild running in the mice (p < 0.05) and at 1 mg/kg, a significant difference in RA was seen (p < 0.05) (Table 1a). Zolantidine (3 and 10...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.